Volume 25, Number 4—April 2019
Research
Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries
Table 2
Model parameter estimates and values used for sensitivity analyses of intervention strategies for screening and treatment of latent TB infection in immigrants*
Parameter | Estimate | Range evaluated in PSA | PSA distribution | References |
---|---|---|---|---|
Screening parameters | ||||
TST sensitivity | 0.782 | 0.69–0.87 | Beta(43,12) | (19) |
TST specificity, no BCG | 0.974 | 0.963–0.982 | Beta(770,21) | (20,21) |
TST specificity, BCG | 0.602 | 0.561–0.642 | Beta(239,158) | (20,21) |
IGRA sensitivity | 0.889 | 0.688–0.993 | Beta(8,1) | (19) |
IGRA specificity | 0.957 | 0.946–0.968 | Beta(900,40) | (20,21) |
IGRA indeterminate† | 0.06 | 0.05–0.07 | Beta(83,1286) | (21) |
Complete TST‡ | 1 | Fixed | Fixed | |
Complete medical evaluation§ |
1 |
Fixed |
Fixed |
|
Population characteristics¶ | ||||
LTBI prevalence | ||||
Very high incidence | 0.3162 | 0.2686–0.3880 | Varied with reactivation rate | (12,15–17) |
High incidence | 0.2016 | 0.1706–0.2464 | Varied with reactivation rate | (12,15–17) |
Moderate incidence | 0.0902 | 0.0763–0.1102 | Varied with reactivation rate | (12,15–17) |
Low incidence | 0.0159 | 0.0135–0.0195 | Varied with reactivation rate | (12,15–17) |
Abnormal chest radiograph results or previous TB | ||||
Very high incidence | 0.039 | Fixed | Fixed | (15) |
High incidence | 0.028 | Fixed | Fixed | (15) |
Moderate incidence | 0.029 | Fixed | Fixed | (15) |
Low incidence | 0.008 | Fixed | Fixed | (15) |
Adherence to postarrival follow-up# |
0.684 |
0.646–0.721 |
Beta(404.50,186.87) |
(22) |
Treatment parameters | ||||
Initiate** | 0.938 | 0.907–0.964 | Beta(180.83,11.95) | (5) |
Complete, INH | 0.616 | 0.561–0.670 | Beta(131.66,82.07) | (5) |
Complete, RIF | 0.814 | 0.745–0.876 | Beta(76.85,17.56) | (5) |
Adverse event, INH | 0.049 | 0.044–0.055 | Beta(249,4789) | (24,25) |
Adverse event, RIF | 0.021 | 0.018–0.025 | Beta(109,4877) | (24,25) |
Adverse event hospitalization | 0.01 | 0.0005–0.03 | Beta(1,99) | (25) |
Death, INH | 0.00000988 | 0–0.00002 | Beta(2,202495) | (26) |
LTBI risk reduction, INH | 0.90 | 0.78–0.95 | Normal(−2.3,0.5)†† | (27) |
LTBI risk reduction, RIF | 0.90 | 0.63–0.97 | Normal(−2.3,0.8)†† | (28,24) |
Partial risk reduction, INH | 0.346 | 0.267–0.490 | Combination of normal distributions††, ‡‡ | Expert opinion, (25) |
Partial risk reduction, RIF | 0.30 | 0.17–0.40 | Normal(−0.35,0.1)†† | Expert opinion, (24,28) |
Adverse event duration |
7 d |
0–24 |
Gamma(0.7,10) |
Expert opinion, (25) |
TB parameters | ||||
Death from TB | 0.0476 | 0.0391–0.0566 | Beta(76,1523) | (3) |
Reactivation rate | 0.0011 | 0.0009–0.0013 | Beta(90.92,82545.55) | (15–17) |
Abnormal CXR risk change | 3.9 | 3.0–4.9 | Normal(1.36,0.15)†† | (29) |
Extended therapy | 0.124 | 0.029–0.264 | Beta(2.366,16.713) | Expert opinion, (30) |
Relapse rate | 0.0359 | 0.0197–0.0654 | Normal(−3.327,0.365)†† | (30) |
Hospitalization duration |
17 d |
Fixed |
Fixed |
Expert opinion, (30) |
Model parameters | ||||
BCG vaccination, <30 cases | 0.605 | 0.60–0.61 | Beta(45137,29502) | (12,13) |
BCG vaccination, ≥30 cases | 0.998 | 0.997–0.999 | Beta(185381,384) | (12,13) |
BCG vaccination uptake | 0.837 | Fixed | Fixed | (14) |
Discount rate | 0.03 | Fixed | Fixed | (23) |
Time horizon | 25 y | Fixed | Fixed | NA |
*AE, adverse event; BCG, bacillus Calmette-Guérin; IGRA, interferon-gamma release assay; INH, isoniazid; LTBI, latent tuberculosis infection; NA, not available; PSA, probabilistic sensitivity analysis; RIF, rifampin; TST, tuberculin skin test; TB, tuberculosis.
†Treated as a negative result if it occurred; was equally likely to occur in those with and without LTBI.
‡Without being mandatory, this value is 63.5% (imputed from 43.4% completing screening when 68.4% adhere with a follow-up appointment) (5).
§Without being mandatory, this value is 78% (imputed from 43.7 of 56 individuals completing medical evaluation) (5).
¶Very high incidence, >200 cases/100,000; high incidence, >100 and <200 cases/100,000; moderate incidence, >30 and <100 cases/100,000; low incidence, <30 cases/100,000.
#From a meta-analysis (22); see also Appendix (https://wwwnc.cdc.gov/EID/article/25/4/17-1630-App1.pdf).
**This model assumes all who report postarrival due to a positive preimmigration LTBI diagnostic test are offered treatment. Exploratory analysis adjusts this assumption so that only the number who would complete TST screening begin treatment.
††Results from this distribution are exponentiated.
‡‡Formula: 0.33 × (Normal(−1.168,0.228)) + 0.374 × (Normal(−0.381,0.169)) + 0.293 × 1.
References
- World Health Organization. Framework towards tuberculosis elimination in low-incidence countries. Geneva: The Organization; 2014 [cited 2018 Mar 7]. http://www.who.int/tb/publications/elimination_framework/en/
- Pareek M, Greenaway C, Noori T, Munoz J, Zenner D. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med. 2016;14:48. DOIPubMedGoogle Scholar
- Taylor Z, Nolan CM, Blumberg HM; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2005;54(RR-12):1–81.PubMedGoogle Scholar
- Campbell J, Marra F, Cook V, Johnston J. Screening immigrants for latent tuberculosis: do we have the resources? CMAJ. 2014;186:246–7. DOIPubMedGoogle Scholar
- Campbell JR, Sasitharan T, Marra F. A systematic review of studies evaluating the cost utility of screening high-risk populations for latent tuberculosis infection. Appl Health Econ Health Policy. 2015;13:325–40. DOIPubMedGoogle Scholar
- Pareek M, Baussano I, Abubakar I, Dye C, Lalvani A. Evaluation of immigrant tuberculosis screening in industrialized countries. Emerg Infect Dis. 2012;18:1422–9. DOIPubMedGoogle Scholar
- Institute of Medicine (US) Committee on the Elimination of Tuberculosis in the United States. Ending neglect: the elimination of tuberculosis in the United States. Geiter L, editor. Washington (DC): National Academies Press; 2000.
- Coker R, van Weezenbeek KL. Mandatory screening and treatment of immigrants for latent tuberculosis in the USA: just restraint? Lancet Infect Dis. 2001;1:270–6. DOIPubMedGoogle Scholar
- Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Möller J; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—4. Value Health. 2012;15:821–7. DOIPubMedGoogle Scholar
- Campbell JR, Chen W, Johnston J, Cook V, Elwood K, Krot J, et al. Latent tuberculosis infection screening in immigrants to low-incidence countries: a meta-analysis. Mol Diagn Ther. 2015;19:107–17. DOIPubMedGoogle Scholar
- Walter ND, Painter J, Parker M, Lowenthal P, Flood J, Fu Y, et al.; Tuberculosis Epidemiologic Studies Consortium. Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med. 2014;189:88–95.PubMedGoogle Scholar
- Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, et al.; Tuberculosis Trials Consortium. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med. 2004;170:1360–6. DOIPubMedGoogle Scholar
- Statistics Canada. Life tables, Canada, provinces, and territories. 2016 [cited 2018 Mar 7]. http://www5.statcan.gc.ca/olc-cel/olc.action?objId=84-537-X&objType=2&lang=en&limit=0
- Marra F, Marra CA, Sadatsafavi M, Morán-Mendoza O, Cook V, Elwood RK, et al. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis. 2008;12:1414–24.PubMedGoogle Scholar
- Menzies D, Lewis M, Oxlade O. Costs for tuberculosis care in Canada. Can J Public Health. 2008;99:391–6.PubMedGoogle Scholar
- Statistics Canada. Consumer price index, annual average, not seasonally adjusted. 2019 [cited 2018 Mar 7]. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1810000501
- Tan MC, Marra CA, Sadatsafavi M, Marra F, Morán-Mendoza O, Moadebi S, et al. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia. Value Health. 2008;11:842–52. DOIPubMedGoogle Scholar
- Fassbender K, Fainsinger RL, Carson M, Finegan BA. Cost trajectories at the end of life: the Canadian experience. J Pain Symptom Manage. 2009;38:75–80. DOIPubMedGoogle Scholar
- Bauer M, Ahmed S, Benedetti A, Greenaway C, Lalli M, Leavens A, et al. The impact of tuberculosis on health utility: a longitudinal cohort study. Qual Life Res. 2015;24:1337–49. DOIPubMedGoogle Scholar
- Tagmouti S, Slater M, Benedetti A, Kik SV, Banaei N, Cattamanchi A, et al. Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review. Ann Am Thorac Soc. 2014;11:1267–76. DOIPubMedGoogle Scholar
- Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM, Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med. 1997;126:210–4. DOIPubMedGoogle Scholar
- Douglas P, Posey DL, Zenner D, Robson J, Abubakar I, Giovinazzo G. Capacity strengthening through pre-migration tuberculosis screening programmes: IRHWG experiences. Int J Tuberc Lung Dis. 2017;21:737–45. DOIPubMedGoogle Scholar
- Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med. 2000;161:780–9. DOIPubMedGoogle Scholar
- Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, Baez J, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med. 2005;353:1008–20. DOIPubMedGoogle Scholar
- Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al.; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–66. DOIPubMedGoogle Scholar
- Byford S, Raftery J. Perspectives in economic evaluation. BMJ. 1998;316:1529–30. DOIPubMedGoogle Scholar
- Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol. 1975;101:363–82. DOIPubMedGoogle Scholar